BioXcel Therapeutics, Inc. Business Finance Contracts & Agreements

First Amendment to Revenue Interest Financing Agreement, dated August 4, 2022, by and between the Company, the purchasers party thereto and Oaktree Fund Administration, LLC, as... (Filed With SEC on May 9, 2023)

Registration Rights Agreement, dated April 19, 2022, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR Strategic Credit... (Filed With SEC on April 19, 2022)

Form of Warrant (Filed With SEC on April 19, 2022)

Underwriting Agreement, dated June 22, 2021, among the Company, the Selling Stockholder and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on June 25, 2021)

Underwriting Agreement, dated July 28, 2020, among the Company, the Selling Stockholders and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on July 31, 2020)

BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on May 21, 2020)

Purchase Agreement, dated February 18, 2020, among the Company and BioXcel Corporation (Filed With SEC on February 21, 2020)

Underwriting Agreement, dated February 19, 2020, among the Company and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on February 21, 2020)

Underwriting Agreement, dated September 26, 2019, between the Company and BMO Capital Markets Corp., as representative of the underwriters named therein (Filed With SEC on September 27, 2019)

Amended and Restated Asset Contribution Agreement, effective November 7, 2017, by and between BioXcel Corporation and BioXcel Therapeutics, Inc (Filed With SEC on February 12, 2018)

Form of Stock Purchase Agreement for September and October 2017 and January and February 2018 Private Placements (Filed With SEC on February 12, 2018)

Grid Note, dated June 30, 2017 (Filed With SEC on February 12, 2018)

Form of Underwriting Agreement (Filed With SEC on February 12, 2018)